Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Common Stockholders' Equity (Deficit) (Unaudited)

v3.22.2.2
Consolidated Statements of Common Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Temporary equity [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Beginning balance at Dec. 31, 2020 $ 12,356 $ 16,651 $ 29,007 $ 1,514 $ (37,954) $ (36,440)
Beginning balance, shares at Dec. 31, 2020 4,612,000 3,489,000   519,000        
Stock-based compensation 1,025 1,025
Foreign currency translation adjustment   16 16
Net loss (16,013) (16,013)
Exercise of stock options 4 $ 4
Exercise of stock options, shares                 5,983
Issuance of Incremental shares to StemoniX shareholders upon Merger
Issuance of Incremental shares to StemoniX shareholders upon Merger, shares         161,000        
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214 $ 1,786 1,786
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214, shares     567,000            
Issuance of Common Stock for acquisition consideration 59,920 59,920
Issuance of Common Stock for acquisition consideration, shares         2,201,000        
Conversion of Preferred Stock to Common Stock upon Merger $ (12,356) $ (16,651) $ (1,786) (30,793) $ 1 30,792 30,793
Conversion of Preferred Stock to Common Stock upon Merger, shares (4,612,000) (3,489,000) (567,000)   2,239,000        
Conversion of 2020 Notes to Common Stock upon Merger 16,190 16,190
Conversion of 2020 Notes to Common Stock upon Merger, shares         668,000        
Preferred stock warrant settled for Common Stock upon Merger
Preferred stock warrant settled for Common Stock upon Merger, shares         9,000        
Warrant liability reclassified to equity upon Merger 421 421
Ending Balance at Sep. 30, 2021 $ 1 109,866 (53,967) 16 55,916
Ending balance, shares at Sep. 30, 2021   5,797,000        
Beginning balance at Jun. 30, 2021         $ 1 109,569 (49,506) (1) 60,063
Beginning balance, shares at Jun. 30, 2021         5,797,000        
Stock-based compensation         297 297
Foreign currency translation adjustment         17 17
Net loss         (4,461) (4,461)
Ending Balance at Sep. 30, 2021 $ 1 109,866 (53,967) 16 55,916
Ending balance, shares at Sep. 30, 2021   5,797,000        
Beginning balance at Dec. 31, 2021         $ 1 110,176 (78,813) (74) 31,290
Beginning balance, shares at Dec. 31, 2021         5,798,000        
Stock-based compensation         1,079 1,079
Foreign currency translation adjustment         148 148
Net loss         (18,431) (18,431)
Exercise of stock options         4   $ 4
Exercise of stock options, shares         1,000       1,034
Vesting of restricted stock        
Vesting of restricted stock, shares         2,000        
Issuance of Incremental shares to StemoniX shareholders upon Merger         (250) (250)
Issuance of Incremental shares to StemoniX shareholders upon Merger, shares         82,000        
Ending Balance at Sep. 30, 2022 $ 1 111,009 (97,244) 74 13,840
Ending balance, shares at Sep. 30, 2022         5,883,000        
Beginning balance at Jun. 30, 2022 $ 1 110,629 (93,781) (62) 16,787
Beginning balance, shares at Jun. 30, 2022         5,883,000        
Stock-based compensation         380 380
Foreign currency translation adjustment         136 136
Net loss (3,463) (3,463)
Ending Balance at Sep. 30, 2022 $ 1 $ 111,009 $ (97,244) $ 74 $ 13,840
Ending balance, shares at Sep. 30, 2022         5,883,000